These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 3904430

  • 1. Aluminum and phosphate: the double bind.
    Kaye M, Gagnon R.
    Am J Kidney Dis; 1985 Nov; 6(5):365-7. PubMed ID: 3904430
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aluminum and the pathogenesis of dialysis encephalopathy.
    Arieff AI.
    Am J Kidney Dis; 1985 Nov; 6(5):317-21. PubMed ID: 3904424
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of plasma aluminum in the detection and prevention of aluminum toxicity.
    Winney RJ, Cowie JF, Robson JS.
    Kidney Int Suppl; 1986 Feb; 18():S91-5. PubMed ID: 3458005
    [No Abstract] [Full Text] [Related]

  • 9. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS, Hercz G, Miller JH, Shinaberger JH, Nissenson AR, Coburn JW.
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aluminum-induced dialysis osteodystrophy: the demise of "Newcastle bone disease"?
    Kerr DN, Ward MK, Arze RS, Ramos JM, Grekas D, Parkinson IS, Ellis HA, Owen JP, Simpson W, Dewar J.
    Kidney Int Suppl; 1986 Feb; 18():S58-64. PubMed ID: 3457998
    [No Abstract] [Full Text] [Related]

  • 13. Aluminum accumulation in individuals with normal renal function.
    Ott SM.
    Am J Kidney Dis; 1985 Nov; 6(5):297-301. PubMed ID: 3933333
    [Abstract] [Full Text] [Related]

  • 14. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG, Andress DL, Milliner DS, Ott SM, Alfrey AC, Slatopolsky EA, Sherrard DJ, Coburn JW.
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract] [Full Text] [Related]

  • 15. Parathyroid hormone in aluminum bone disease: a comparison of parathyroid hormone assays.
    Andress DL, Endres DB, Ott SM, Sherrard DJ.
    Kidney Int Suppl; 1986 Feb; 18():S87-90. PubMed ID: 3458004
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU, Becker GJ, Kincaid-Smith PS.
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ, Walker JV, Boykin JL.
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [Abstract] [Full Text] [Related]

  • 20. Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia.
    Phelps KR, Einhorn TA, Vigorita VJ, Lundin AP, Friedman EA.
    ASAIO Trans; 1986 Aug; 32(1):198-200. PubMed ID: 3778712
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.